Andy

REPROCELL USA is proud to announce that it has received funding from MSCRF for both proposals it has submitted for the MSCRF’s January 2024 grant cycle. These two grants will help us produce Master Cell Banks (MCB) for cell therapy and enhance our capacity to produce therapeutic cell products.

BELTSVILLE, Md., June 5, 2024 /PRNewswire/ — REPROCELL is a leader in producing clinically relevant human induced pluripotent stem cells (hiPSCs). These hiPSCs are generated from healthy donors that have been screened for eligibility using the questionnaire established by the US Food & Drug Administration (FDA). Further viral testing is performed to satisfy the requirements of FDA, European Medicines Agency (EMA) and Pharmaceutical and Medical Devices Agency (PMDA) of Japan. The first grant titled: “Generation of human iPSC and MSC MCBs and derivative products in an enclosed GMP system” will help REPROCELL offer two GMP grade cell lines in the next 8 to 12 months for commercialization. These products will be tested for quality and ready for off-the-shelf distribution and further differentiation internally, by other companies in Maryland and the rest of the world. This grant is funded by MSCRF under their commercialization grant that provides funding for commercializing the products.

ROCKVILLE, Md., June 5, 2024 /PRNewswire/ — I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY). The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab and ABL Bio (KOSDAQ: 298380), with Bristol Myers Squibb’s immune checkpoint inhibitor, nivolumab, and chemotherapy (FOLFOX or CAPOX), as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers.

Montgomery County, Maryland, is a top destination for the life sciences industry. Pete Briskman, JLL’s Executive Managing Director and Chair of BioHealth Innovation Inc.’s (BHI) Board of Directors, highlights several reasons why.

“Montgomery County is poised well in comparison to other regions,” Briskman said, pointing to its proximity to NIH and FDA and the strong talent pipeline from local universities.

Briskman also emphasized creative real estate solutions and the region’s strengths in cell and immunotherapy research. “Health care isn’t going away,” he noted, reflecting optimism about the sector’s growth.

Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the recently announced master collaboration agreement between the two companies.

Washington, D.C., June 03, 2024 (GLOBE NEWSWIRE) — Children’s National Hospital is pleased to welcome Alda Mizaku in a newly established role of vice president and chief data and artificial intelligence officer (CDAIO). In this role, Mizaku will lead the execution of enterprise data, analytics and artificial intelligence (AI) strategy at Children’s National.

Mizaku has a track record of leading initiatives with measurable organizational value, from reducing unnecessary length of stay to enhancing operational efficiency and patient outcomes. Prior to joining Children’s National, Mizaku spent 11 years working for Mercy Health System in St. Louis, where she served in various roles, including executive director of Data Engineering and Analytics, and vice president of Analytics Product Management.

At BioHealth Innovation Inc. (BHI), we are happy to celebrate the achievements of our partner company, miRecule, which has recently been named a winner at the INVEST Pitch Perfect competition. miRecule’s innovative approach to RNA therapies represents a significant advance in the treatment of cancer and muscular dystrophy. By leveraging genomic data to design highly specific therapeutics, miRecule stands at the forefront of personalized medicine, underscoring our commitment to supporting ground-breaking healthcare solutions.

This recognition is not just a win for miRecule; it’s a testament to the power of strategic partnerships and the impact of innovative biotechnological advances in addressing complex health challenges. BHI is proud to be associated with pioneers like miRecule, as we continue to foster a thriving ecosystem that brings revolutionary treatments from the lab to the patients who need them most.